These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33337365)

  • 1. Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials.
    Hasegawa K; Kochi K; Maruyama H; Konishi O; Toya S; Odawara T
    J Alzheimers Dis; 2021; 79(2):627-637. PubMed ID: 33337365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data.
    Tousi B; Leverenz JB
    Drug Des Devel Ther; 2021; 15():1811-1817. PubMed ID: 33976533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.
    Murata M; Odawara T; Hasegawa K; Kajiwara R; Takeuchi H; Tagawa M; Kosaka K
    Parkinsonism Relat Disord; 2020 Jul; 76():91-97. PubMed ID: 31982288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study.
    Murata M; Odawara T; Hasegawa K; Iiyama S; Nakamura M; Tagawa M; Kosaka K
    Neurology; 2018 Feb; 90(8):e664-e672. PubMed ID: 29367449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial.
    Odawara T; Hasegawa K; Kajiwara R; Takeuchi H; Tagawa M; Kosaka K; Murata M
    Am J Geriatr Psychiatry; 2022 Mar; 30(3):314-328. PubMed ID: 34420834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials.
    Tsuboi Y; Kochi K; Maruyama H; Matsumoto Y
    eNeurologicalSci; 2022 Mar; 26():100384. PubMed ID: 34988303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review.
    Kong L; Xi J; Jiang Z; Yu X; Liu H; Wang Z
    Biomed Res Int; 2022; 2022():4817488. PubMed ID: 36132085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12-week multicentre, randomised, double-blind, and placebo-controlled phase IV study.
    Mori E; Ikeda M; Iseki E; Katayama S; Nagahama Y; Ohdake M; Takase T
    Psychogeriatrics; 2024 May; 24(3):542-554. PubMed ID: 38439118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study.
    Ikeda M; Mori E; Orimo S; Yamada T; Konishi O
    J Alzheimers Dis; 2023; 95(1):251-264. PubMed ID: 37483001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinesterase inhibitors for dementia with Lewy bodies.
    Wild R; Pettit T; Burns A
    Cochrane Database Syst Rev; 2003; 2003(3):CD003672. PubMed ID: 12917981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
    Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG
    Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial.
    Ikeda M; Mori E; Matsuo K; Nakagawa M; Kosaka K
    Alzheimers Res Ther; 2015; 7(1):4. PubMed ID: 25713599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donepezil for dementia with Lewy bodies: meta-analysis of multicentre, randomised, double-blind, placebo-controlled phase II, III, and, IV studies.
    Mori E; Ikeda M; Ohdake M
    Psychogeriatrics; 2024 May; 24(3):589-596. PubMed ID: 38439217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
    Emre M; Tsolaki M; Bonuccelli U; Destée A; Tolosa E; Kutzelnigg A; Ceballos-Baumann A; Zdravkovic S; Bladström A; Jones R;
    Lancet Neurol; 2010 Oct; 9(10):969-77. PubMed ID: 20729148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invited Perspective on the "Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial".
    Hinkle JT; Pontone GM
    Am J Geriatr Psychiatry; 2022 Mar; 30(3):329-331. PubMed ID: 34429237
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Aboulatta L; Haidar L; Abou-Setta A; Askin N; Rabbani R; Lavu A; Peymani P; Zarychanski R; Eltonsy S
    CNS Drugs; 2023 Nov; 37(11):941-956. PubMed ID: 37973769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
    Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
    Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism.
    Panza F; Lozupone M; Watling M; Imbimbo BP
    Expert Opin Pharmacother; 2021 Feb; 22(3):325-337. PubMed ID: 33021110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.
    Cummings JL; Street J; Masterman D; Clark WS
    Dement Geriatr Cogn Disord; 2002; 13(2):67-73. PubMed ID: 11844887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months.
    Matar E; White SR; Taylor JP; Thomas A; McKeith IG; Kane JPM; Surendranathan A; Halliday GM; Lewis SJG; O'Brien JT
    Neurology; 2021 Sep; 97(10):e1031-e1040. PubMed ID: 34404743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.